LF 20-0383
Alternative Names: LF 216Latest Information Update: 05 Oct 2007
At a glance
- Originator Fournier Pharma
- Class
- Mechanism of Action Interleukin 8 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Adult respiratory distress syndrome; Chronic obstructive pulmonary disease; Rheumatoid arthritis
Most Recent Events
- 07 Jan 2004 No development reported - Preclinical for Adult respiratory distress syndrome in France (unspecified route)
- 07 Jan 2004 No development reported - Preclinical for Chronic obstructive pulmonary disease in France (unspecified route)
- 07 Jan 2004 No development reported - Preclinical for Rheumatoid arthritis in France (unspecified route)